RMC-9805

RMC-9805 is a novel, mutant-selective, covalent and oral KRASG12D (ON) inhibitor. A stable and high affinity triple complex is formed between RMC-9805, KRASG12D, and cyclophilin A, which inhibits signal transduction downstream of KRASG12D (ON) by disrupting its interaction with downstream effectors. RMC-9805 can induce cell apoptosis and promote tumor regression in preclinical KRASG12D tumor models. With rich experience in compound synthesis, we can provide fast customized synthesis services for this product according to your research needs.

C(C(F)(F)F)N1C(=C2C=3C1=CC=C(C3)N4C[C@](C[C@H](NC([C@@H](N5C[C@@]6(CC5)CN(C(=O)[C@H]7[C@H](N7C)[C@@H]8CC8)CC6)[C@H]9CCCC9)=O)C(=O)N%10N[C@](C(=O)OCC(C)(C)C2)(CCC%10)[H])(OCC4)[H])C%11=C([C@@H](OC)C)N=CC(=C%11)N%12CCN(CC%12)C%13CC%13